BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 27465265)

  • 1. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
    Inzucchi SE; Viscoli CM; Young LH; Furie KL; Gorman M; Lovejoy AM; Dagogo-Jack S; Ismail-Beigi F; Korytkowski MT; Pratley RE; Schwartz GG; Kernan WN;
    Diabetes Care; 2016 Oct; 39(10):1684-92. PubMed ID: 27465265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
    Kernan WN; Viscoli CM; Furie KL; Young LH; Inzucchi SE; Gorman M; Guarino PD; Lovejoy AM; Peduzzi PN; Conwit R; Brass LM; Schwartz GG; Adams HP; Berger L; Carolei A; Clark W; Coull B; Ford GA; Kleindorfer D; O'Leary JR; Parsons MW; Ringleb P; Sen S; Spence JD; Tanne D; Wang D; Winder TR;
    N Engl J Med; 2016 Apr; 374(14):1321-31. PubMed ID: 26886418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
    Young LH; Viscoli CM; Curtis JP; Inzucchi SE; Schwartz GG; Lovejoy AM; Furie KL; Gorman MJ; Conwit R; Abbott JD; Jacoby DL; Kolansky DM; Pfau SE; Ling FS; Kernan WN;
    Circulation; 2017 May; 135(20):1882-1893. PubMed ID: 28246237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
    Yaghi S; Furie KL; Viscoli CM; Kamel H; Gorman M; Dearborn J; Young LH; Inzucchi SE; Lovejoy AM; Kasner SE; Conwit R; Kernan WN;
    Circulation; 2018 Jan; 137(5):455-463. PubMed ID: 29084736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
    Kernan WN; Inzucchi SE; Viscoli CM; Brass LM; Bravata DM; Shulman GI; McVeety JC; Horwitz RI
    Stroke; 2003 Jun; 34(6):1431-6. PubMed ID: 12730556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
    Kernan WN; Viscoli CM; Dearborn JL; Kent DM; Conwit R; Fayad P; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH;
    JAMA Neurol; 2017 Nov; 74(11):1319-1327. PubMed ID: 28975241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
    Young LH; Viscoli CM; Schwartz GG; Inzucchi SE; Curtis JP; Gorman MJ; Furie KL; Conwit R; Spatz ES; Lovejoy A; Abbott JD; Jacoby DL; Kolansky DM; Ling FS; Pfau SE; Kernan WN;
    Circulation; 2018 Sep; 138(12):1210-1220. PubMed ID: 29934374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
    Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb PA; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN;
    Am Heart J; 2014 Dec; 168(6):823-9.e6. PubMed ID: 25458644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
    Spence JD; Viscoli CM; Inzucchi SE; Dearborn-Tomazos J; Ford GA; Gorman M; Furie KL; Lovejoy AM; Young LH; Kernan WN;
    JAMA Neurol; 2019 May; 76(5):526-535. PubMed ID: 30734043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.
    Furie KL; Viscoli CM; Gorman M; Ford GA; Young LH; Inzucchi SE; Guarino PD; Lovejoy AM; Conwit R; Tanne D; Kernan WN;
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):21-27. PubMed ID: 28939682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to study drug in a stroke prevention trial"?>.
    Kiran A; Viscoli CM; Furie KL; Gorman M; Kernan WN
    J Stroke Cerebrovasc Dis; 2020 Oct; 29(10):105048. PubMed ID: 32912514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
    Viscoli CM; Inzucchi SE; Young LH; Insogna KL; Conwit R; Furie KL; Gorman M; Kelly MA; Lovejoy AM; Kernan WN;
    J Clin Endocrinol Metab; 2017 Mar; 102(3):914-922. PubMed ID: 27935736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.